SWOG clinical trial number
S0014

Evaluation of CHOP Plus Rituximab Plus Involved Field Radiotherapy for Stages I, IE, and Non-Bulky Stages II and IIE, CD20 Positive, High Risk Localized Aggressive Histologies of Non-Hodgkin’s Lymphoma, Phase II

Closed
Phase
Accrual
100%
Published
Abbreviated Title
NON-HODGKIN'S: CHOP with concurrent rituximab plus IFR
Activated
04/01/2000
Closed
01/15/2002
Participants
NCORP, Members, Medical Oncologists, Pathologists

Research committees

Lymphoma

Treatment

Cyclophosphamide Prednisone Vincristine Doxorubicin Rituximab Radiation Therapy CHOP RT

Eligibility Criteria Expand/Collapse

Hist. proven Non-Hodgkin's lymphoma of one of the following subtypes: diffuse large B-cell, mantle cell, high-grade B-cell, Burkitt's or Burkitt-like, anaplastic large cell(B-cell phenotype only); Stage I, IE or non-bulky II or IIE; CD20 positive; at least one of the following adverse prognostic features: non-bulky Stage II or non-bulky Stage IIE, age > = 60 years, Zubrod status of 2, serum LDH > IULN; no prior RT for lymphoma; no prior monoclonal antibody treatment; pre-reg. radiation oncology consult at SWOG approved RT facility; bone marrow aspirate and biopsy; chest x-ray or chest CT; CT of abdomen/pelvis; > = 18 years; no contraindications to CHOP chemotherapy; no known AIDS or HIV.

Publication Information Expand/Collapse

2022

Extranodal presentation in limited stage DLBCL as a prognostic marker in three SWOG trials S0014, S0313 and S1001 [Letter to Editor]

D Stephens;H Li;L Constine;T Fitzgerald;J Leonard;B Kahl;M LeBlanc;S Smith;JW Friedberg;D Persky Haematologica Nov 1;107(11):2732-2736

PMid: PMID35833300 | PMC number: PMC9614528

2021

Extranodal presentation in limited stage DLBCL as a prognostic marker in three sequential SWOG trials S0014, S0313 and S1001 (NCT00005089, NCT00070018, NCT01359592)

D Stephens;H Li;L Constine;T Fitzgerald;J Leonard;Kahl;J Song;M LeBlanc;S Smith;JW Friedberg;D Persky American Society of Hematology (Dec 11-14, 2021, Atlanta, GA), poster presentation, #1423

2014

Genetic polymorphisms in oxidative stress-related genes are associated with outcomes following treatment for aggressive B-cell non-Hodgkin lymphoma

H Gustafson (Tardif);S Yao;B Goldman;K Lee;C Spier;M LeBlanc;L Rimsza;JR Cernan;TM Habermann;BK Link;MJ Mauer;SL Slager;D Persky;T Miller;RI Fisher;C Ambrosone;M Briehl American Journal of Hematology 89(6):639-645;

PMid: PMID24633940 | PMC number: PMC4137041

2008

Phase II study of rituximab plus three cycles of CHOP and involved-field radiotherapy for patients with early-stage aggressive B-cell lymphoma: Southwest Oncology Group Study 0014. [PMID 18413640]

DO Persky;JM Unger;CM Spier;B Stea;M LeBlanc;MJ McCarty;LM Rimsza;RI Fisher;TP Miller Journal of Clinical Oncology 26(14)2258-2263

2004

Effect of adding rituximab to three cycles of CHOP plus invoved-field radiotherapy for limited-stage aggressive diffuse B-cell lymphoma (SWOG-0014).

TP Miller;JM Unger;C Spier;B Stea;E Cantu;M LeBlanc;RI Fisher Blood 104(11): #158

Other Clinical Trials

SWOG Clinical Trial Number
S2207

Randomized Phase II Study of the Addition of Targeted Therapeutic Agents to Tafasitamab-Based Therapy in Non-Transplant-Eligible Patients with Relapse/Refractory Large B-Cell Lymphoma
Research Committee(s)
Lymphoma
Activated
06/30/2023
Accrual
6%
Open
Phase
SWOG Clinical Trial Number
CTSU/AHOD2131

A Randomized Phase 3 Interim Response Adapted Trial Comparing Standard Therapy with Immuno-oncology Therapy for Children and Adults with Newly Diagnosed Stage I and II Classic Hodgkin Lymphoma
Research Committee(s)
Lymphoma
Immunomolecular Therapeutics
Activated
04/28/2023
Open
Phase
SWOG Clinical Trial Number
S2114

A Randomized Phase II trial of consolidation therapy following CD19 CAR T-cell treatment for Relapsed/Refractory Diffuse Large B-cell Lymphoma or Grade IIIB Follicular Lymphoma
Research Committee(s)
Lymphoma
Activated
02/23/2023
Accrual
11%
Open
Phase